(Q36414326)

14 August 2017

title

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study (English)

1 reference

metastatic renal cell carcinoma

14 August 2017

0 references

1 reference

1 reference

Hans J Hammers

1

1 reference

14 August 2017

Elizabeth R Plimack

2

1 reference

14 August 2017

Jeffrey R Infante

3

1 reference

14 August 2017

Brian I Rini

4

1 reference

14 August 2017

David F McDermott

5

1 reference

14 August 2017

Lionel D Lewis

6

1 reference

14 August 2017

Martin H Voss

7

1 reference

14 August 2017

Padmanee Sharma

8

1 reference

14 August 2017

Sumanta K Pal

9

1 reference

14 August 2017

Albiruni R Abdul Razak

10

1 reference

14 August 2017

Christian Kollmannsberger

11

1 reference

14 August 2017

Daniel Y C Heng

12

1 reference

14 August 2017

Jennifer Spratlin

13

1 reference

14 August 2017

M Brent McHenry

14

1 reference

14 August 2017

Asim Amin

15

1 reference

14 August 2017

language of work or name

English

0 references

publication date

5 July 2017

1 reference

Journal of Clinical Oncology

14 August 2017

published in

1 reference

14 August 2017

page(s)

JCO2016721985

1 reference

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

14 August 2017

cites work

1 reference

12 December 2020

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

12 December 2020

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

1 reference

12 December 2020

Emerging immunotherapies for renal cell carcinoma

1 reference

12 December 2020

Role of cytokine therapy for renal cell carcinoma in the era of targeted agents.

1 reference

12 December 2020

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

12 December 2020

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

1 reference

12 December 2020

Karnofsky performance status revisited: reliability, validity, and guidelines

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Systemic therapy in metastatic renal cell carcinoma

1 reference

12 December 2020

Current and future systemic treatments for renal cell carcinoma

1 reference

12 December 2020

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review

1 reference

12 December 2020

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

1 reference

12 December 2020

Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors

1 reference

12 December 2020

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

1 reference

12 December 2020

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

1 reference

12 December 2020

Nivolumab plus ipilimumab in advanced melanoma

1 reference

12 December 2020

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

1 reference

12 December 2020

Identifiers

DOI

10.1200/JCO.2016.72.1985

1 reference

14 August 2017

0 references

1 reference